title: [Central serous chorioretinopathy and systemic diseases report of 2 cases associated with corticotherapy].
abstract: BACKGROUND
  Central serous chorioretinopathy is an uncommon retinal disease, whose pathogenesis is largely unknown. It is characterized by an accumulation of subretinal fluid at the posterior pole of the fundus, creating a circumscribed area of serous retinal detachment. It manifests generally as a visual loss or an abnormal colour vision. It is often idiopathic but may also be associated with numerous pathological situations, with frequent exposure to corticosteroids.
  
  
  METHODS
  We report on two patients with central serous chorioretinopathy. The first female patient had been treated with steroids for a systemic lupus erythematosus for fifteen years, and the second male patient had been treated with steroids for an idiopathic hypereosinophilic syndrome for a few months. Visual loss led to a diagnosis of central serous chorioretinopathy. Lowering of steroids doses was followed by a clinical improvement in both cases.
  
  
  CONCLUSIONS
  Similarly to cataract or glaucoma, central serous chorioretinopathy belongs to the potential ocular side-effect of steroid treatment, and thus deserves to be known by internists.
authors.affiliation: Service de médecine interne, CHU de Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
authors.forename: A
authors.initials: A
authors.lastname: Bouyon
authors.forename: N
authors.initials: N
authors.lastname: Costedoat-Chalumeau
authors.forename: N
authors.initials: N
authors.lastname: Limal
authors.forename: C
authors.initials: C
authors.lastname: Fardeau
authors.forename: B
authors.initials: B
authors.lastname: Bodaghi
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: J-C
authors.initials: JC
authors.lastname: Piette
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D002825:Chorioretinitis / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008297:Male; D012163:Retinal Detachment / Q000139:chemically induced; D013997:Time Factors; D014792:Visual Acuity
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents